Sanofi

Linguamatics' I2E natural language processing engine helps Sanofi match HLA alleles with multiple sclerosis and associated drug treatments.

The firms will use Adaptive's ClonoSeq assay to assess minimal residual disease in multiple myeloma patients treated with Sanofi's isatuximab.

The partnership includes biopharmaceutical, life science, and non-profit organizations, as well as several US government agencies.

Berg will use its Interrogative Biology platform in order to assess potential biomarkers of seasonal influenza vaccination outcomes.

To Interfere

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

The companies will use Myriad RBM's CustomMAP platform to measure cardiovascular risk biomarkers in patients treated with a Sanofi diabetes drug.

Sanofi recruits one of AstraZeneca's top scientists to bolster its biotech presence, Reuters reports.

The collaboration will focus on identifying new signaling pathways and targets involved in coronary artery disease.

The study used a modified version of Myriad RBM's DiscoveryMAP immunoassay panel to measure levels of 237 proteins in blood samples from 8,401 patients.

The pharma firm joins Pfizer Canada and AstraZeneca in the National Access Project, which tests tumors for mutations to match patients with potential therapies.

Pages

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.